Vaccinex previously reported that on October 10, 2023 it was advised by Nasdaq that the Company was no longer in compliance with Nasdaq’s minimum bid price requirement and that Nasdaq could move to suspend trading of the common stock and to delist the Company’s securities unless the company appealed Nasdaq’s determination. The Company appealed that decision and has been granted an exception until March 4, 2024 to address this issue. Subject to fulfilling its commitments to Nasdaq, it is expected that Vaccinex shares will continue to be listed on the Nasdaq Capital Market throughout this time and subsequently if compliance is restored. Vaccinex continues to advance its key programs with particular focus on a potential near-term catalyst, the randomized phase 2 trial of its pepinemab antibody to counter neuroinflammation in Alzheimer’s disease. The last patient in this trial is expected to complete the planned 12-months of treatment by early June 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VCNX:
- Vaccinex reports Q3 EPS ($1.09) vs. ($1.67) last year
- Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Vaccinex reports clinical benefit in interim analyses from Phase 2 studies
- Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases
- Vaccinex announces presentation of findings for pepinemab